Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Masimo Corporation - Common Stock (NQ: MASI )

190.47 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Masimo Corporation - Common Stock

< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
Masimo CEO Joe Kiani Appointed to President’s Council of Advisors on Science and Technology
From Masimo
Via Business Wire
Masimo Launches Single-patient-use rainbow® SuperSensor™
From Masimo
Via Business Wire
Masimo to Present in Morgan Stanley 19th Annual Global Healthcare Conference
From Masimo Corporation
Via Business Wire
Earnings Scheduled For July 27, 2021
Companies Reporting Before The Bell • Navios Maritime Partners (NYSE:NMM) is projected to report quarterly earnings at $2.93 per share on revenue of $146.03 million.... 
Via Benzinga
New Study Investigates the Ability of Masimo ORi™ to Provide Early Warning of Hypoxemia During Endotracheal Intubation in ICU Patients
From Masimo
Via Business Wire
Masimo Partners with Penington Institute to Raise Awareness of Harm from Prescription Opioid Overdose
From Masimo
Via Business Wire
Masimo SafetyNet Alert™ Launches in Western Europe
From Masimo
Via Business Wire
Society for the Advancement of Patient Blood Management (SABM) Publication Recommends Continuous Hemoglobin Monitoring
From Masimo
Via Business Wire
The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug
ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 23) AbbVie Inc. (NYSE: ABBV) (... 
Via Benzinga
Exposures Product Safety
New Study Evaluates the Use of Masimo PVi® to Monitor Volume Status in Spontaneously Breathing Hemodialysis Patients
From Masimo
Via Business Wire
New Study Evaluates the Use of Masimo Bridge® As an Alternative to Opioids
From Masimo
Via Business Wire
Masimo (MASI) Q2 2021 Earnings Call Transcript
MASI earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Masimo: Q2 Earnings Insights
Shares of Masimo (NASDAQ:MASI) moved lower in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 10.59% year over year to $... 
Via Benzinga
Masimo Reports Second Quarter 2021 Financial Results
From Masimo
Via Business Wire
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI... 
Via Benzinga
Masimo Earnings Preview
On Tuesday, July 27, Masimo (NASDAQ:MASI) will report its last quarter's earnings. Here is Benzinga's preview of the company's release. Net Income, Earnings, And Earnings Per... 
Via Benzinga
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
Exposures Product Safety
Masimo Introduces the MX-7™ rainbow SET® Technology Board for Original Equipment Manufacturing Partners
From Masimo
Via Business Wire
Masimo to Report Second Quarter 2021 Financial Results after Market Close on Tuesday, July 27
From Masimo
Via Business Wire
New Study Evaluates the Ability of Masimo SedLine® Brain Function Monitoring to Predict Neurological Outcomes and Long-term Survival in Post-Cardiac Arrest ICU Patients
From Masimo
Via Business Wire
Masimo's Wearable Thermometer Scores FDA Approval For Prescription, OTC Use
Masimo (NASDAQ: MASI) has announced that Radius Tº, a wearable, wireless thermometer, has received FDA 510(k) clearance for both prescription and over-the-... 
Via Benzinga
Exposures Product Safety
Masimo Announces FDA 510(k) Clearance of Radius Tº™ for Prescription and Over-the-Counter (OTC) Use
From Masimo
Via Business Wire
Inflation Fears and Stock Market News
Plus, best-selling author Daniel Kahneman shares insights from his new book, "Noise: A Flaw in Human Judgment." 
Via The Motley Fool
New Study Investigates the Impact of ORi-Guided Oxygen Titration on Hyperoxemia-Mediated Morbidity During One-Lung Ventilation
From Masimo
Via Business Wire
Masimo to Present in UBS Global Healthcare Virtual Conference
From Masimo
Via Business Wire
New Study Assesses the Effects of Masimo Patient SafetyNet™ on Nursing Workflows in the General Ward
From Masimo
Via Business Wire
Study Investigates the Ability of Masimo O3® to Aid in Monitoring Septic Shock ICU Patients and Predicting Mortality
From Masimo
Via Business Wire
Study Investigates the Ability of Masimo PVi® to Predict Preload Responsiveness in Patients On Nasal High-Flow Therapy
From Masimo
Via Business Wire
Masimo (MASI) Q1 2021 Earnings Call Transcript
MASI earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.